tradingkey.logo

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

ReutersJan 12, 2026 12:35 PM

- Nuvation Bio Inc NUVB.N:

  • NUVATION BIO AND EISAI ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR TALETRECTINIB IN EUROPE AND ADDITIONAL COUNTRIES OUTSIDE U.S., CHINA AND JAPAN

  • NUVATION BIO INC - TO RECEIVE UP TO €195 MILLION IN PAYMENTS

  • NUVATION BIO INC - EISAI RECEIVES EXCLUSIVE RIGHTS FOR TALETRECTINIB IN MULTIPLE REGIONS

  • NUVATION BIO INC: MAA FOR TREATMENT OF ADVANCED ROS1+ NSCLC IS EXPECTED TO BE FILED IN EUROPE IN FIRST HALF OF 2026

  • NUVATION BIO INC - MAA FOR TALETRECTINIB EXPECTED IN EUROPE IN 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI